KRAS and dengue disease: Since the E-427 (Chew et al., 2017), NS3-5 (Majerova et al., 2019), and NS5-833 (Nascimento et al., 2021) residues have been applied as target regions when anti-DENV agents designs, it might be necessary to verify the potency of anti-DENV agents as treatments when developing novel drugs in severe dengue patients in the future.